The same drug development news that's hurting Eli Lilly shares might be good for Amgen and Sanofi-Regeneron.» Read More
Specialists are protesting a big overnight increase in the price of a drug for treating a life-threatening parasitic infection.
A liberal think tank wants drugs priced according to how effective they are relative to existing medications.
Surgeons may soon plan out their operations with personalized 3-D printed replicas of their patient's organs.
Uncertainty around emerging markets may spook investors on fears of a global economic slowdown, but drugmaker Novartis is not reining in its plans.
171 million doses of flu vaccine have been produced for this season.
Activity trackers are designed to help users get healthy, but many people stop using them within months.
Perrigo rejected Mylan's unsolicited $27 billion tender offer, saying it undervalued the company and did not adequately compensate shareholders.
A new study on blood pressure could not only impact one in three Americans, but also a major part of the drug industry.
The FDA and a government task force are clashing over a new report on benefits and risks of daily aspirin doses. NBC News reports.
The "Halftime Report" traders toss around some 'under the radar' plays.
Government-run health exchanges had increased coverage options for customers in 2015.
The current number of Obamacare sign-ups is still ahead of an official 9.1 million customer year-end goal.
Young people who smoke electronic cigarettes are much more likely to smoke tobacco ciggies within a year than their peers.
Is Valeant Pharmaceuticals CEO Mike Pearson the Billy Beane of pharma deals?
Market turmoil can affect more than your 401K — it can take a toll on your health, says Dr. Florence Comite.
Mylan said it will go directly to Perrigo Pharmaceuticals investors starting on Sept. 14 with its $27 billion cash and stock offer.
Concordia Healthcare said it would buy Amdipharm Mercury for $1.9 billion to expand its portfolio of drugs aimed at treating rare diseases.
Insurance mergers "threaten ... widespread competitive harm," doctor and hospital groups warn regulators. New York Times reports.
Almost 1 out of every 3 HealthCare.gov plans want rate hikes of more than 10 percent next year.
The chief executive of Philip Morris told CNBC he wants their lines of e-cigarettes eventually to outsell traditional smokes.
Get the best of CNBC in your inbox